EP1890690A4 - Inhibiteurs de la mao-b utilises pour traiter l'obesite - Google Patents

Inhibiteurs de la mao-b utilises pour traiter l'obesite

Info

Publication number
EP1890690A4
EP1890690A4 EP06771748A EP06771748A EP1890690A4 EP 1890690 A4 EP1890690 A4 EP 1890690A4 EP 06771748 A EP06771748 A EP 06771748A EP 06771748 A EP06771748 A EP 06771748A EP 1890690 A4 EP1890690 A4 EP 1890690A4
Authority
EP
European Patent Office
Prior art keywords
abesity
mao
treating
inhibitors useful
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06771748A
Other languages
German (de)
English (en)
Other versions
EP1890690A2 (fr
Inventor
John F Mcelroy
Robert J Chorvat
Parthasarathi Rajagopalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenrin Discovery LLC
Original Assignee
Jenrin Discovery LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenrin Discovery LLC filed Critical Jenrin Discovery LLC
Publication of EP1890690A2 publication Critical patent/EP1890690A2/fr
Publication of EP1890690A4 publication Critical patent/EP1890690A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
EP06771748A 2005-06-02 2006-06-01 Inhibiteurs de la mao-b utilises pour traiter l'obesite Withdrawn EP1890690A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68658505P 2005-06-02 2005-06-02
PCT/US2006/021142 WO2006130707A2 (fr) 2005-06-02 2006-06-01 Inhibiteurs de la mao-b utilises pour traiter l'obesite

Publications (2)

Publication Number Publication Date
EP1890690A2 EP1890690A2 (fr) 2008-02-27
EP1890690A4 true EP1890690A4 (fr) 2010-06-02

Family

ID=37482280

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06771748A Withdrawn EP1890690A4 (fr) 2005-06-02 2006-06-01 Inhibiteurs de la mao-b utilises pour traiter l'obesite

Country Status (10)

Country Link
US (2) US7649115B2 (fr)
EP (1) EP1890690A4 (fr)
JP (1) JP5253155B2 (fr)
CN (1) CN101300006B (fr)
AU (1) AU2006252540B2 (fr)
CA (1) CA2620476A1 (fr)
IL (1) IL187825A (fr)
NZ (1) NZ564130A (fr)
WO (1) WO2006130707A2 (fr)
ZA (1) ZA200800036B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI361075B (en) * 2007-03-16 2012-04-01 Brion Res Inst Of Taiwan Pharmaceutical composition for inhibiting the syndrome of snore
EP2053033A1 (fr) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Composants à utiliser dans l'imagerie, le diagnostic et/ou le traitement des maladies du système nerveux central ou des tumeurs
IT1392914B1 (it) * 2009-01-22 2012-04-02 Dipharma Francis Srl Procedimento per la preparazione di (r)-n-propargil-1-amminoindano e suoi sali
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
CN107056630B (zh) * 2017-01-23 2020-01-17 合肥工业大学 一种茚满类衍生物及其合成方法和在医药上的用途
NZ762985A (en) 2017-09-22 2024-03-22 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
HUE061607T2 (hu) 2017-10-18 2023-07-28 Jubilant Epipad LLC Imidazopiridin vegyületek mint PAD inhibitorok
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
EP3704120B1 (fr) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Composés hétérocycliques utilisés en tant qu'inhibiteurs de prmt5
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas
WO2022269439A1 (fr) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Méthode de régulation du taux de glycémie et de traitement du diabète et d'affections apparentées

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0538134A2 (fr) * 1991-10-16 1993-04-21 Teva Pharmaceutical Industries, Ltd. Dérivés mono-fluorés de N-propargyl-1-aminoindane et leur usage comme inhibiteurs de monoamine oxidase
US5786390A (en) * 1990-01-03 1998-07-28 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
EP1078632A1 (fr) * 1999-08-16 2001-02-28 Sanofi-Synthelabo Utilisation des inhibiteurs de monoamine oxydases dans la fabrication d'un médicament contre l'obésité
US6462222B1 (en) * 1996-12-18 2002-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminoindan derivatives
WO2003072055A2 (fr) * 2002-02-27 2003-09-04 Teva Pharmaceutical Industries, Ltd. Derives de propargylaminoindane et derives de propargylaminotetraline utilises comme inhibiteurs de la mao cerebro-selectifs
US20040068016A1 (en) * 2001-08-31 2004-04-08 Aventis Pharma Deutschland Gmbh C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
WO2005084205A2 (fr) * 2004-02-27 2005-09-15 Teva Pharmaceutical Industries, Ltd. Derives de diamino-thiazoloindan et utilisation de ceux-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) 1965-08-17 Chsx c cech
US3253037A (en) 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
MXPA04006119A (es) * 2001-12-21 2004-11-01 Lundbeck & Co As H Derivados aminoindano como inhibidores de la absorcion de la serotonina y de la norepinefrina.
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
EP1686973A4 (fr) * 2003-11-25 2009-03-25 Technion Res & Dev Foundation Compositions et procedes pour traiter des troubles et des maladies cardiovasculaires
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
JP2008531546A (ja) 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786390A (en) * 1990-01-03 1998-07-28 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
EP0538134A2 (fr) * 1991-10-16 1993-04-21 Teva Pharmaceutical Industries, Ltd. Dérivés mono-fluorés de N-propargyl-1-aminoindane et leur usage comme inhibiteurs de monoamine oxidase
US6462222B1 (en) * 1996-12-18 2002-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminoindan derivatives
EP1078632A1 (fr) * 1999-08-16 2001-02-28 Sanofi-Synthelabo Utilisation des inhibiteurs de monoamine oxydases dans la fabrication d'un médicament contre l'obésité
US20040068016A1 (en) * 2001-08-31 2004-04-08 Aventis Pharma Deutschland Gmbh C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
WO2003072055A2 (fr) * 2002-02-27 2003-09-04 Teva Pharmaceutical Industries, Ltd. Derives de propargylaminoindane et derives de propargylaminotetraline utilises comme inhibiteurs de la mao cerebro-selectifs
WO2005084205A2 (fr) * 2004-02-27 2005-09-15 Teva Pharmaceutical Industries, Ltd. Derives de diamino-thiazoloindan et utilisation de ceux-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KENNEDY S H ET AL: "IS THERE A ROLE FOR SELECTIVE MONOAMINE OXIDASE INHIBITOR THERAPY IN BULIMIA NERVOSA? A PLACEBO-CONTROLLED TRIAL OF BROFAROMINE", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, WILLIAMS AND WILKINS, US, vol. 13, no. 6, 1 December 1993 (1993-12-01), pages 415 - 422, XP000879189, ISSN: 0271-0749 *
N. PIZZINAT ET AL: "High Expression of Monoamine Oxidases in Human White Adipose Tissue: Evidence for Their Involvement in Noradsrenaline Clearance", BIOCHEMICAL PHARMACOLOGY, vol. 58, 1 July 1999 (1999-07-01), pages 1735 - 1742, XP002577474 *

Also Published As

Publication number Publication date
AU2006252540B2 (en) 2011-12-01
EP1890690A2 (fr) 2008-02-27
AU2006252540A1 (en) 2006-12-07
ZA200800036B (en) 2008-12-31
WO2006130707A3 (fr) 2007-01-18
US20100168068A1 (en) 2010-07-01
US7649115B2 (en) 2010-01-19
WO2006130707A2 (fr) 2006-12-07
JP5253155B2 (ja) 2013-07-31
US8541475B2 (en) 2013-09-24
JP2008542386A (ja) 2008-11-27
IL187825A0 (en) 2008-03-20
US20070088004A1 (en) 2007-04-19
IL187825A (en) 2012-08-30
CN101300006B (zh) 2012-07-25
CN101300006A (zh) 2008-11-05
CA2620476A1 (fr) 2006-12-07
NZ564130A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
EP1890690A4 (fr) Inhibiteurs de la mao-b utilises pour traiter l'obesite
HK1122738A1 (en) Trpa1 inhibitors for treating pain
ZA200804238B (en) Agents for treating cardiopathy
AP2870A (en) Odcase inhibitors for the treatment of malaria
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
EP1926485A4 (fr) Inhibiteurs du facteur de transcription hif
IL186445A0 (en) Dna-pk inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
IL187881A0 (en) Sphingosine kinase inhibitors
IL183889A0 (en) Treatment method
EP1940397A4 (fr) Methodes de traitement de l'hypertension
GB0704718D0 (en) Compounds and methods for preventing and treating mucositis
EP1963462A4 (fr) Inhibiteur de la corrosion
EP1921078A4 (fr) Inhibiteur de multikinase
ZA200800591B (en) Mao-B inhibitors useful for treating obesity
IL190081A0 (en) Nnrt inhibitors
ZA200903771B (en) Carbamate compounds for use in treating depression
EP1910272A4 (fr) Inhibiteurs de la renine
EP1883405A4 (fr) Methodes de traitement de la nephrolithiase
EP1944124A4 (fr) Procédé de grenaillage
GB0515327D0 (en) Comt inhibitors
TWI349958B (en) Substrate treating apparatus
GB0608357D0 (en) Method for treating effluent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 217/54 20060101ALI20100420BHEP

Ipc: C07C 229/46 20060101ALI20100420BHEP

Ipc: A61K 31/27 20060101AFI20070906BHEP

Ipc: A61P 3/04 20060101ALI20100420BHEP

Ipc: C07C 269/00 20060101ALI20100420BHEP

Ipc: C07D 307/68 20060101ALI20100420BHEP

Ipc: C07C 311/08 20060101ALI20100420BHEP

Ipc: C07C 235/06 20060101ALI20100420BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100503

17Q First examination report despatched

Effective date: 20120117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151231